![Peter D. Ho](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter D. Ho
Plus aucun poste en cours
Profil
Peter D.
Ho worked as a Director of Business Development at Iovance Biotherapeutics, Inc. and as Head of Business Development & Licensing at ImmunoCellular Therapeutics Ltd.
He holds a Master's in Business Administration from the University of California, Los Angeles and a doctorate from the University of California San Diego.
Anciens postes connus de Peter D. Ho
Sociétés | Poste | Fin |
---|---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | - |
EOM PHARMACEUTICALS HOLDINGS, INC. | Corporate Officer/Principal | - |
Formation de Peter D. Ho
University of California, Los Angeles | Masters Business Admin |
University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
Sociétés cotées | 1 |
---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
ImmunoCellular Therapeutics Ltd.
![]() ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |